Key clinical point: About 50% of patients with facial vitiligo who were on the two highest doses of topical ruxolitinib had a 50% decrease in depigmentation after 6 months of treatment.
Major finding: At 24 weeks, 50% on ruxolitinib cream 1.5% once daily had 50% clearing, as did 45.5% of those on ruxolitinib cream twice daily (P less than .0001 vs. placebo for both).
Study details: Randomized, double-blind, vehicle-controlled phase 2b study of 157 adult patients with facial and body vitiligo.
Disclosures: Dr. Rosmarin reported financial relationships with numerous pharmaceutical companies, including Incyte, which funded the study.
REPORTING FROM WCD2019
This Week's Must Reads
Must Reads in Mixed Topics
Link Found Between AD, Depression, Suicidal Ideation , J Am Acad Dermatol; 2019 Feb; Patel, et al
Patients with Persistent Post-Chemotherapy Alopecia, JAMA Dermatol; ePub 2019 Mar 6; Freites-Martinez, et al
Patients with HS Have Pyoderma Gangrenosum Risk, J Am Acad Dermatol; ePub 2019 Feb 6; Tannenbaum, et al
Telangiectases Location and Distribution in Youth, J Am Acad Dermatol; ePub 2019 Feb 25; Gonzalez, et al